Cagrilintide vs Semaglutide

Written by Aaron CuhaReviewed Sep 2026

The short answer

A drug that copies the hormone amylin, against a GLP-1 drug. These are the two halves of CagriSema.

Cagrilintide people: 5,752
Cagrilintide nulls: 0
Semaglutide people: 42,363
Semaglutide nulls: 2

Dose

Doses used in trials

0.3, 0.6, 1.2 and 2.4 mg

Doses used in the cagrilintide trials, in mg. Not an approved ladder.

Dose

Approved titration: 0.25, 0.5, 1, 1.7 and 2.4 mg

0.25, 0.5, 1, 1.7 and 2.4 mg

The approved semaglutide ladder, in mg.

First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.

Column A

Cagrilintide

Cagrilintide (long-acting amylin receptor agonist)

A weekly shot being tested with semaglutide as a pair called CagriSema. Together they took off more weight than either one alone. It is not approved.

Column B

Semaglutide

Semaglutide (GLP-1 receptor agonist)

A once a week shot for type 2 diabetes and weight loss. It is approved, and big studies show it also lowers the risk of heart attack and stroke.

Side by side, on the facts we can check

What we compare	Cagrilintide	Semaglutide
Category	Metabolic	Metabolic
FDA status	Investigational, not FDA-approved	FDA-approved (Ozempic and Rybelsus for type 2 diabetes; the Wegovy shot, the Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management)
Half-life	~7 days	~7 days
Molecular weight	~3,700 Da	4,113.6 Da
How it works	It works on amylin receptors in the parts of the brain that control hunger. That helps you feel full and slows how fast food leaves your stomach. This adds to what GLP-1 drugs like semaglutide do.	It switches on the GLP-1 receptor, a switch on cells that normally answers a gut hormone after you eat. That makes the body release insulin when blood sugar is high. It holds back glucagon, a hormone that raises blood sugar. It slows how fast the stomach empties. It also acts on the part of the brain that runs hunger, so people eat less.
Studies in people	5	15
Evidence	Strong: 5 completed trials, 5,752 people given it	Strong: 12 completed trials, 42,363 people given it
Legal status, US	Investigational, not approved	FDA-approved, prescription only

open the Cagrilintide profile open the Semaglutide profile

Frequently asked questions

What is the difference between Cagrilintide and Semaglutide?

Cagrilintide: A weekly shot being tested with semaglutide as a pair called CagriSema. Together they took off more weight than either one alone. It is not approved. Semaglutide: A once a week shot for type 2 diabetes and weight loss. It is approved, and big studies show it also lowers the risk of heart attack and stroke.

Which has stronger research evidence, Cagrilintide or Semaglutide?

Each compound gets a band worked out from facts we counted, with the math shown. Cagrilintide is Strong (5 completed trials, 5,752 people given it). Semaglutide is Strong (12 completed trials, 42,363 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.

Are Cagrilintide and Semaglutide FDA-approved?

Cagrilintide: Investigational, not FDA-approved. Semaglutide: FDA-approved (Ozempic and Rybelsus for type 2 diabetes; the Wegovy shot, the Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).

Blog articles that cover Cagrilintide or Semaglutide, newest first.

Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.

Side by side, on the facts we can check

Frequently asked questions

Related posts